The value of the quality adjusted life years

19 June 2024 - Concerns about quality-adjusted life years (QALYs) being discriminatory have reached a fever pitch in the US, culminating ...

Read more →

What good are whizzy new drugs if the world can’t afford them?

14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...

Read more →

ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access

5 June 2024 - This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs ...

Read more →

ICER publishes evidence report on treatment for chronic obstructive pulmonary disease

30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...

Read more →

Institute for Clinical and Economic Review publishes evidence report on treatment for post-traumatic stress disorder

14 May 2024 - There are substantial uncertainties around the clinical trial results; given the inability to assess net benefit, ...

Read more →

ICER releases draft evidence report on treatment for anaemia in myelodysplastic syndrome

9 May 2024 - Public comment period now open until 10 June 2024; requests to make oral comment during public ...

Read more →

ICER to assess treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease

2 May 2024 - Report will be subject of New England CEPAC meeting in November 2024; draft scoping document open ...

Read more →

ICER and NEWDIGS release white paper analysing the challenges and potential policy options for paying for gene therapies

23 April 2024 - Paper outlines policy reforms and market actions to support innovation and access while managing uncertainty, affordability, ...

Read more →

ICER releases draft evidence report on treatment for chronic obstructive pulmonary disease

10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...

Read more →

ICER publishes 2024 research protocol for assessing unsupported price increases on prescription drugs

9 April 2024 - Input period now open until 13 May 2024. ...

Read more →

ICER releases draft evidence report on treatment for post-traumatic stress disorder

26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...

Read more →

ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria

13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...

Read more →

ICER publishes final evidence report on treatment for schizophrenia

11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...

Read more →

ICER to assess treatments for transthyretin amyloidosis cardiomyopathy

7 March 2024 - Report will be subject of Midwest CEPAC meeting in September 2024; draft scoping document open to ...

Read more →

ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria

1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...

Read more →